Bethanechol Chloride information from DrugsUpdate  

Pharmacodynamics

Pharmacokinetics

Distribution
Does not cross blood-brain barrier.
Onset
Oral
30 min.
Subcutaneous
5 to 15 min.
Peak
Oral
60 to 90 min.
Duration
Oral
1 h, up to 6 h for larger doses.
Subcutaneous
2 h.

Bethanechol Chloride Indications / Bethanechol Chloride Uses

Treatment of acute postoperative and postpartum nonobstructive urinary retention and neurogenic atony of the urinary bladder with retention.

Bethanechol Chloride Adverse Reactions / Bethanechol Chloride Side Effects

Nausea, vomiting, abdominal cramps, diarrhoea, frequency of micturition; blurred vision; tachycardia, flushing; headache, malaise.

Precautions

Monitor
Establish baseline BP and pulse and monitor BP, pulse, and voiding patterns. Notify health care provider if urinary retention persists.

Special Precautions

Urinal Retention

Other Drug Interactions

Cholinergic agents
Possible toxicity because of additive effects.
Ganglionic blocking compounds
Severe hypotension, usually preceded by severe abdominal symptoms.
Quinidine or procainamide
Antagonism of anticholinergic effects of bethanechol.

Other Interactions

Information Not Available

Dosage

Oral
Urinary Retention:
Adult- 10-50mg 3-4 times daily.

Food(before/after)

Information Not Available

Bethanechol Chloride and Pregnancy

Category C

Bethanechol Chloride and Lactation

Undetermined

Bethanechol Chloride and Children

Safety and efficacy not established

Bethanechol Chloride and Geriatic

Information Not Available

Bethanechol Chloride and Other Contraindications

Hyperthyroidism; peptic ulcer; latent or active asthma; pronounced bradycardia; AV conduction defects; vasomotor instability; coronary artery disease; epilepsy; parkinsonism; coronary occlusion; hypotension; hypertension; bladder neck obstruction; spastic GI disturbances; acute inflammatory lesions of the GI tract; peritonitis; marked vagotonia. Not used when strength or integrity of GI or bladder wall is in question or in presence of mechanical obstruction, when increased muscular activity of GI tract or urinary tract may prove harmful (eg, after recent urinary bladder surgery, GI resection and anastomosis, possible GI obstruction).

Storage

Store tablets at controlled room temperature (59° to 86°F). Keep tightly closed. Avoid storage of injection at less than -4°F and more than 104°F.

Lab interference

Store tablets at controlled room temperature (59° to 86°F). Keep tightly closed. Avoid storage of injection at less than -4°F and more than 104°F.